Literature DB >> 10491728

Pharmacological properties of indapamide. Rationale for use in hypertension.

A Bataillard1, P Schiavi, J Sassard.   

Abstract

Indapamide is a thiazide-related diuretic drug with antihypertensive properties. Its blood pressure-lowering action has been repeatedly demonstrated in acute as well as chronic conditions in various genetically and nongenetically determined forms of hypertension. In rats, the maximally effective oral dose is 3 mg/kg/24 h. The natriuretic effect of indapamide peaked at 3-fold at a dose of 1 mg/kg. In accordance with its antihypertensive properties, indapamide was shown to have excellent efficacy in protecting against target organ damage (heart, kidneys, brain). In addition to its natriuretic effect, it has been shown in several experiments that indapamide lowers the response to sympathetic nerve stimulation, exhibits calcium antagonist properties, enhances the production of prostacyclin, and limits the production of free radicals and of endothelium-dependent vasoconstrictor substances. These effects, even though they are observed at high indapamide concentrations and in a possibly species-dependent manner, may contribute to the beneficial properties of indapamide. The most recent data suggest that low doses of indapamide exert synergistic effects in combination with other antihypertensive drugs such as ACE inhibitors, the effects of which are influenced by the sodium status of the organism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10491728     DOI: 10.2165/00003088-199937001-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  26 in total

1.  Effects of indapamide on Ca2+ entry into vascular smooth muscle cells.

Authors:  G Zempel; J Ditlevsen; M Hoch; U Emerich; H Heinle; P Schiavi; F Dubois; F Lang
Journal:  Nephron       Date:  1997       Impact factor: 2.847

2.  Radical scavengers of indapamide in prostacyclin synthesis in rat smooth muscle cell.

Authors:  Y Uehara; H Shirahase; T Nagata; T Ishimitsu; S Morishita; S Osumi; H Matsuoka; T Sugimoto
Journal:  Hypertension       Date:  1990-02       Impact factor: 10.190

3.  The link among nitric oxide synthase activity, endothelial function, and aortic and ventricular hypertrophy in hypertension.

Authors:  H Hayakawa; L Raij
Journal:  Hypertension       Date:  1997-01       Impact factor: 10.190

4.  The diuretic indapamide increases bone mass and decreases bone resorption in spontaneously hypertensive rats supplemented with sodium.

Authors:  A Lalande; C Roux; A M Graulet; P Schiavi; M C De Vernejoul
Journal:  J Bone Miner Res       Date:  1998-09       Impact factor: 6.741

5.  Antioxidant properties of indapamide, 5-OH indapamide and hydrochlorothiazide evaluated by oxygen-radical absorbing capacity and electron paramagnetic resonance.

Authors:  C Vergely; M K Walker; M Zeller; J R Rademakers; V Maupoil; P Schiavi; D Guez; L Rochette
Journal:  Mol Cell Biochem       Date:  1998-01       Impact factor: 3.396

Review 6.  The coronary circulation in cardiac hypertrophy.

Authors:  D J Sheridan; A McAinsh; D J O'Gorman
Journal:  J Cardiovasc Pharmacol       Date:  1993       Impact factor: 3.105

7.  Thiazide diuretic agents and the incidence of hip fracture.

Authors:  A Z LaCroix; J Wienpahl; L R White; R B Wallace; P A Scherr; L K George; J Cornoni-Huntley; A M Ostfeld
Journal:  N Engl J Med       Date:  1990-02-01       Impact factor: 91.245

8.  Carotid artery mechanical properties of Dahl salt-sensitive rats.

Authors:  A Benetos; H Bouaziz; P Albaladejo; D Guez; M E Safar
Journal:  Hypertension       Date:  1995-02       Impact factor: 10.190

9.  Action of indapamide on excitation-contraction coupling in vascular smooth muscle.

Authors:  J Mironneau; Y M Gargouil
Journal:  Eur J Pharmacol       Date:  1979-07-15       Impact factor: 4.432

10.  Effects of indapamide on atherosclerosis development in cholesterol-fed rabbits.

Authors:  M Del Rio; T Chulia; A Merchan-Perez; M Remezal; S Valor; J Gonzalez; J A Gutierrez; J A Contreras; M A Lasuncion; T Tejerina
Journal:  J Cardiovasc Pharmacol       Date:  1995-06       Impact factor: 3.105

View more
  6 in total

Review 1.  Current status of sustained release formulations in the treatment of hypertension. An overview.

Authors:  E Mutschler; H Knauf
Journal:  Clin Pharmacokinet       Date:  1999       Impact factor: 6.447

2.  Not just chlorthalidone: evidence-based, single tablet, diuretic alternatives to hydrochlorothiazide for hypertension.

Authors:  George C Roush; Michael E Ernst; John B Kostis; Ramandeep Kaur; Domenic A Sica
Journal:  Curr Hypertens Rep       Date:  2015-04       Impact factor: 5.369

Review 3.  A review of the prescribing trend of thiazide-type and thiazide-like diuretics in hypertension: A UK perspective.

Authors:  Ryan J McNally; Franca Morselli; Bushra Farukh; Philip J Chowienczyk; Luca Faconti
Journal:  Br J Clin Pharmacol       Date:  2019-12-09       Impact factor: 4.335

Review 4.  Perindopril/indapamide 2/0.625 mg/day: a review of its place in the management of hypertension.

Authors:  A J Matheson; S M Cheer; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 5.  Indapamide sustained release: a review of its use in the treatment of hypertension.

Authors:  Dean M Robinson; Keri Wellington
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 6.  Delapril plus indapamide: a review of the combination in the treatment of hypertension.

Authors:  Luca Cavalieri; Giovanni Cremonesi
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.